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trafﬁckingThe endoplasmic reticulum (ER) is the principal organelle responsible for the proper folding/processing of
nascent proteins and perturbed ER function leads to a state known as ER stress. Mammalian cells try to overcome
ER stress through a set of protein signaling pathways and transcription factors termed the unfolded protein
response (UPR). However, under unresolvable ER stress conditions, the UPR is hyperactivated inducing cell
dysfunction and death. The accumulation of misfolded proteins in the brain of Alzheimer's disease (AD) patients
suggests that alterations in ER homeostasis might be implicated in the neurodegenerative events that character-
ize this disorder. This review discusses the involvement of ER stress in the pathogenesis of AD, focusing the
processing and trafﬁcking of the AD-related amyloid precursor protein (APP) during disease development. The
potential role of ER as a therapeutic target in AD will also be debated.
© 2014 Elsevier B.V. All rights reserved.1. Endoplasmic reticulum stress
The endoplasmic reticulum (ER) was ﬁrst described in 1945 as an
extensive network of interconnected membrane tubules that spread
throughout the cytosol [1]. A large number of studies showed that the
ER can be divided into three domains according to its structure andfolded protein response; AD,
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pt (P.I. Moreira).function: 1) the nuclear envelope, which controls the ﬂow of informa-
tion between the cytoplasm and the nucleus, 2) the sheet-like cisternae,
also denominated rough ER due to thehigh content in ribosomes, and 3)
the polygonal array of tubules, also called smooth ER [1,2]. This highly
dynamic and multifunctional organelle is implicated in protein quality
control along the secretory pathway being responsible for protein fold-
ing, assembly and post-translational modiﬁcations (e.g. glycosylation,
disulﬁde bond formation), among other functions.
1.1. The unfolded protein response and its role in cell survival and apoptosis
Perturbations of ER homeostasis, triggered by several factors includ-
ing ER Ca2+ depletion, oxidative stress andmutated proteins that trafﬁc
through the secretory pathway can be responsible for the accumulation
of misfolded/malfolded proteins in its lumen leading to ER stress. To re-
establish homeostasis, the ER activates the unfolded protein response
(UPR) [3,4], which prevents the aggregation and facilitates the folding
of damaged proteins, decreases translation to prevent overload of ER
lumen with newly synthesized proteins, increases ER biogenesis and
volume through the stimulation of lipid synthesis and activates protein
degradation via the ER-associated protein degradation (ERAD) pathway
[5–7].
In mammals, the mechanisms implicated in the ER stress response
are poorly understood. The most accepted hypothesis defends that the
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stress sensors protein kinase RNA (PKR)-like ER kinase (PERK), activat-
ing transcription factor 6 (ATF6) and inositol-requiring enzyme-1alpha
(IRE1α) [4]. Under ER stress, GRP78/BiP dissociates from these sensors
and promotes their activation, inducing phosphorylation and oligomer-
ization of PERK and IRE1α and the translocation of ATF6 to the Golgi
where it is cleaved [4]. Once activated, the ER stress sensors increase
several transcription factors and control the expression of chaperones
and other modulators of protein quality control within the secretory
pathway [4]. After the onset of ER stress, the activation of the three
branches of the UPR occurs in a time-dependent manner (Fig. 1) [8,9].
Upon activation, PERKphosphorylates eIF2α on the serine 51 of itsα
subunit, which leads to the inhibition of delivery of the initiator
methionyl-tRNA to the ribosome, resulting in general inhibition of
protein translation [9,10]. Paradoxically, eIF2α phosphorylation also
promotes the translation of selective mRNAs that contain the internal
entry ribosomal site (IRES), leading to the translation of genes associated
with UPR, namely the transcription factor gene 4 (ATF4) [10,11]. This
transcription factor is responsible for the up-regulation of genes associat-
ed with redox homeostasis, energy metabolism and protein folding [3,4].
The activation of IRE1α triggers the selective degradation of mRNAs
encoding for proteins with abnormal folding, induces the unconven-
tional splicing of the mRNA encoding the transcription factor XboxFig. 1. The unfolded protein response (UPR). Perturbation of endoplasmic reticulum(ER) homeo
protein-1 (XBP1), protein kinase RNA (PKR)-like ER kinase (PERK) and inositol-requiring enz
78 kDa glucose-regulated protein (GRP78/BIP). However, the accumulation of incorrectly fol
which become activated. Active PERK phosphorylates the eukaryotic initiation factor-2alpha (
ER. eIF2α also activates the transcription factor ATF4, which up-regulates UPR target genes en
activation of IRE1α leads to non-canonical XBP1 splicing. This spliced formofXBP1 (sXBP1), alon
of UPR target genes. Activated ATF6 migrates to the nucleus to stimulate the expression of genbinding protein-1 (XBP1), which shifts the coding reading frame and
leads to the expression of a more stable and active transcription factor,
XBP1s. XBP1s is responsible for the regulation of a subset of UPR target
genes related with protein folding, ER/Golgi biogenesis and ERAD,
namely endoplasmic reticulum DnaJ homolog 4 (ERdj4), protein
kinase inhibitor of 58 kDa (p58IPK), ER degradation-enhancing α-
mannosidase-like protein (EDEM), ribosome-associated membrane
protein 4 (RAMP-4), protein disulﬁde isomerase P5 (PDI-P5) and HEDJ
[12]. In addition, IRE1α interacts with several adaptor proteins, such
as c-Jun NH(2)-terminal kinase (JNK), apoptosis signal-regulating
kinase 1 (ASK1), the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB), and can thus trigger autophagy, apoptosis
and/or an inﬂammatory response [4].
ATF6 is a membrane-spanning protein that after dissociation from
GRP78/BiP translocates to the Golgi where it is activated through
proteolytic processing. In the nucleus, active ATF6 induces the expression
of genes associated with protein quality control mechanisms [13]. This
transcription factor can act synergistically with XBP1s [3].
Although the UPR is activated in order to restore organelle and
cellular homeostasis, prolonged UPR activation can trigger apoptosis
(Fig. 2) [4,14]. Besides the pro-survival effect discussed above, the
IRE1α/XBP1 pathway has an important role in apoptosis. Indeed, the
phosphorylation of IRE1α by the c-Jun-N-terminal inhibitory kinasestasis triggers adaptive signaling cascades associated to the ER stress sensors Xbox binding
yme-1alpha (IRE1α). These ER sensors are inactivated through the interaction with the
ded proteins in the ER lumen detaches GRP78/BIP from these transmembrane proteins,
eIF2α) at serine 51 reducing protein synthesis and, consequently, protein overload in the
coding factors involved in amino acids biosynthesis, the antioxidant stress response. The
e or synergisticallywith activating transcription factor 6 (ATF6), activates the transcription
es containing the ER stress response element (ERSE) and the UPR elements.
Fig. 2. Endoplasmic reticulum (ER) stress-mediated apoptosis. Unresolved ER stress induces apoptotic cell death through different mechanisms. The release of Ca2+ from ER causes the
activation of resident caspase-12 that initiates a caspase cascade. Activating transcription factor 4 (ATF4) induces apoptosis through activation of the transcription factor CHOP/
GADD153, which in turn up-regulates pro-apoptotic Bcl2 family members such as Bax and Bak and down-regulates anti-apoptotic members namely Bcl-xL. The pro-apoptotic members
of the Bcl2 family may trigger apoptosis in a mitochondria-dependent pathway that involves translocation of Bax and Bak from the ER to themitochondria and also activation of caspases
through the release of cytochrome c (Cyt C) from mitochondria. The phosphorylation of c-Jun N-terminal kinase (JNK) that occurs upon interaction of IRE1α and tumor necrosis factor
(TNF) receptor-associated factor 2 (TRAF2) also activates the transcription factor CHOP/GADD153.
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factor-2 (TRAF2). The complex IRE1–TRAF2 activates caspase-12 and a
downstream caspase cascade is activated [15]. The complex IRE1–
TRAF2 also activates a Jun NH(2)-terminal kinase (JNK)-mediated apo-
ptotic pathway [15]. IRE1α also promotes the selective degradation of
mRNAs encoding proteins of the secretory pathway, a process called
regulated IRE1-dependent decay (RIDD) [16]. Initially, RIDD was
proposed as an adaptive mechanism to reduce the overload of proteins
in the secretory pathway but recent studies suggested that RIDD-
mediated degradation of mRNA that encode ER chaperones such as
GRP78/BiP acts as a pro-apoptotic stimulus. Sustained activation of
PERK can induce the major pro-apoptotic transcription factor C/EBP
homologous protein CHOP/GADD153 [17], which up-regulates the
ER oxidase 1α (ERO1α), leading to excessive generation of oxidant
species and depletion of the antioxidant glutathione [18,19] and also to
the release of Ca2+ from the ER through the IP3R [20,21]. In addition,
the ER stress-induced transcription factor CHOP/GADD153 can down-
regulate the anti-apoptotic Bcl-2 and up-regulate the pro-apoptotic
proteins Bax and Bak [21].
The ATF6 signaling pathway seems to predominantly play a pro-
survival role and only few evidence links ATF6 and cell death. Recently,this transcription factor has been associated with the down-regulation
of the anti-apoptotic Mcl-1 in myoblasts during differentiation, however
this effect has not been reported in an ER stress context [22,23].
1.2. ER calcium homeostasis and crosstalk with mitochondria
In the ER, the homeostasis of Ca2+ ismaintained due to the concerted
action of Ca2+ pumps that actively uptake Ca2+, Ca2+-binding proteins
that allow the storage of Ca2+ in the ER lumen and Ca2+ channels that
release Ca2+ into the cytosol in response to several stimuli [4,19,24].
The Ca2+ channels associated with the ER receptors for IP3 (IP3R) and
ryanodine (RyR) are present at the mitochondria-associated membrane
(MAM), which is responsible for the communication between the ER
and themitochondria [4,25].MAMallows the formationof Ca2+microdo-
mains that ensure an efﬁcient transfer of Ca2+between ER andmitochon-
dria, essential for energetic metabolism and cell survival [4]. ER-to-
mitochondria Ca2+ transfer can be regulated by the ER chaperone
Sigma-1 receptor (Sigma-1R) [4,26]. Impairment of Ca2+ coupling
between the ER andmitochondria can lead to apoptosis [27] and is tightly
modulated bymembers of the Bcl-2 family [28]. The induction of apopto-
sis depends of the amount of anti- and pro-apoptotic proteins at the ER
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through the interaction with the IP3R, however the underlying mecha-
nisms remain unknown [28]. It was shown that the deletion of pro-
apoptotic proteins Bax and Bak promotes the interaction between IP3R
and anti-apoptotic Bcl-2 family members, consequently decreasing
Ca2+ released from ER stores [28–30].
It was hypothesized that the presence of Bax at the ER surface under
ER stress conditions is responsible for the release of Ca2+ from ER by
blocking the interaction between Bcl-xL and the IP3R subsequently
leading to the activation of the ER resident caspase-12 [29,30]. In
rodents, caspase-12 is an ERmembrane pro-apoptotic cysteine protease
activated under ER stress conditions. This caspase was silenced in
humans by evolutionary mutations and it is believed that caspase-4
plays a similar role to caspase-12 in rodents [31]. The activation of
caspase-12 occurs through cleavage of its prodomain and cleaved
caspase-12 activates the apoptosis' effector caspase-3 via caspase-9,
independently of cytochrome c and Apaf-1 [31–33].
In summary, the UPR is a stress response strategy that regulates
protein folding/misfolding at the ER and controls cell fate. This protein
quality controlmechanismoperating at the ER is able to trigger adaptive
and protective pathways, however, chronic UPR activation in neurode-
generative diseases such as Alzheimer's disease (AD) can have a negative
impact on cell survival since it affects the folding and trafﬁcking of
proteins through the secretory pathway [34,35].2. Alzheimer's disease and ER stress
AD is the most common form of dementia in the elderly, which
affects more than 30 million people worldwide and 10 million in
Europe [36] and it is believed that AD pathogenesis is related to the
synergistic interaction between ageing and a multitude of cellular,
biochemical and genetic factors. Mutations in presenilin 1 (PS1),
presenilin 2 (PS2) and amyloid precursor protein (APP) lead to early-
onset familial AD, prior to age 65. Speciﬁc polymorphisms in apolipopro-
tein E are associated with risk to develop the most frequent, late-onset
form of AD, occurring after 65 years [37].
The clinical symptoms of AD are characterized by a progressive
cognitive deterioration together with impairments in behavior,
language, and visuospatial skills, culminating in the premature death of
the individual. These traits are accompanied by neuropathological
features observed in postmortem AD brains, including a selective neuro-
nal and synaptic loss in cortical and subcortical regions, deposition of
extracellular senile plaques, mainly composed of amyloid β (Aβ)
peptide, presence of intracellular neuroﬁbrillary tangles (NFT)
containing hyperphosphorylated tau protein, and cerebral amyloid
angiopathy [38].
A growing number of studies suggest that Aβ interferes with ER
functioning leading to ER stress in early stages of AD progression
[39–41]. In fact, it was shown that exogenous Aβ induces ER stress
in primary neuronal cultures and activates mitochondria- and ER-
mediated cell death pathways [42–44]. In PC12 cells and knock-in
mice expressing mutant PS1 it was shown that the up-regulation of
protein levels of CHOP/GADD153 was followed by the down-regulation
of the anti-apoptotic protein Bcl-2. Concomitantly, the authors observed
that mutant PS1 sensitizes cells to the deleterious effects of ER stress
culminating in cell death, this effect being attenuated by anti-sense-
mediated suppression of CHOP/GADD153 production [45]. In the hippo-
campus of the triple transgenic mouse model of AD (3xTg-AD)
increased levels of CHOP/GADD153 precede the increase in BACE and
Aβ levels [46].
In AD brains, the ER stressmarker GRP78/BiP is positively correlated
with Braak staging [40]. Moreover, analysis of AD postmortem brain
revealed an alteration in protein levels of several ER stress markers,
namely GRP78/BiP, protein disulﬁde isomerase (PDI), PERK, eIF2α
posphorylation and IRE1α [4,47–54].3. The amyloid precursor protein
3.1. APP structure and function
APP is a type I transmembrane protein formed by a large extracellular
N-terminal domain, a transmembrane domain and a short C-terminal
cytoplasmic domain composed of 59 amino acids residues [55]. Although
APP can be detected in all tissues, it is highly expressed in the brain. In
mammals, the APP gene is located in the long arm of the chromosome
21. There are eight isoforms of APP, generated by alternative splicing,
that range from 365 to 770 amino acids residues and the most common
isoforms contain 695, 751 and 770 amino acids. The 695 isoform is highly
expressed in the central nervous system (CNS) and the others are ubiqui-
tously expressed in all tissues.
Since the identiﬁcation of APP as the precursor protein of Aβ a large
number of physiological functions have been proposed to APP. In 1993,
Nishimoto et al. [56] suggested that the cytoplasmic domain of APP is a
receptor coupled to a guanosine triphosphate (GTP)-binding protein.
Studies involving APP overexpression demonstrated that it positively
modulates cell survival and growth [57,58]. Saitoh et al. [59] showed
that the normal growth of ﬁbroblasts that harbor an antisense construct
of APP can be restored with the administration of the secreted form of
APP (sAPP). Accordingly, sAPP was demonstrated to reduce neuronal
apoptosis in models of traumatic brain injury [60]. However, in 2009
Oh et al. [61] observed that in both transgenic mouse models with the
familial AD Swedish mutation and mice carrying wild type APP the
overexpression of APP increases the percentage ofmediumsize neurons
and decreases the percentage of small-sized neurons suggesting that
APP induces the hypertrophy of neurons that was believed to be a
compensatory mechanism or a reaction to neuronal injury. Similarly,
Leyssen et al. [62] showed that APP promotes neurite arborization
using a drosophila model of brain injury. APP also plays an important
role in the maintenance and formation of synapses, neuronal survival
and neuritic outgrowth [63–66]. In the embryonic cortex of rodents
the knock down of APP was found to be responsible for abnormal synap-
tic activity and neuronal migration [67–69]. Moreover, in 2009 it was
proposed that APP ectodomain can act as a ligand for the death receptor
6 (DR6) and, according to the studies of Nikolaev et al. [70], growth factor
deprivation triggers APP cleavage byβ-secretase (BACE) 1 resulting in the
release of APP ectodomain, which binds to DRP6 and activates caspase-3
and caspase-6 inducing apoptosis. APP may also act as an adhesion
molecule or adhesion receptor of growth cones [71]. Indeed, this pro-
tein is highly expressed in axons and has the ability to bind to extracellu-
lar matrix components such as collagen I, glypican, heparin and co-
localize with integrins and laminin [69,72–75]. Finally, it was proposed
that the C-terminal domain of APP acts as a transcriptional regulator of
its own intracellular sorting [76]. Despite the numerous studies reporting
the relevance of APP in neuronal cells, others show that APP knockout
causes only subtle phenotypic alterations [77–79]. These discrepancies
need to be carefully examined to uncover the importance of APP, partic-
ularly in the CNS.
Aβ itself plays an important role in synaptic regulation. In addition, it
was suggested that neuronal activity regulates, at least in part, the
production of Aβ, supporting the idea that this peptide has a physiological
function [80,81]. Accordingly, some studies showed that small increases
of Aβ levels, within the physiological range, enhance the release of synap-
tic vesicles and increase neuronal activity [76,82].
3.2. Role of ER stress in APP processing and trafﬁcking
Despite the large number of studies devoted to clarify the mecha-
nisms involved in the processing of APP, it is presently unclear if different
APP isoforms are processed by the same metabolic pathway and if they
similarly trigger the amyloidogenic pathway. It is known that APP protein
has three main proteolytic cleavage sites that lead to APP processing
through distinct catabolic pathways. More than 90% of APP is cleaved by
1448 A.I. Plácido et al. / Biochimica et Biophysica Acta 1842 (2014) 1444–1453the non-amyloidogenic pathway involving the zinc metalloproteinase
α-secretase, releasing a secreted form of APP (sAPPα). The C-terminal
fragment (C-88) that is retained in the membrane is subsequently
cleaved by a γ-secretase generating a short fragment called p3 and a
cytoplasmic fragment identiﬁed as the APP intracellular domain (AICD).
In the non-amyloidogenic pathway, α-secretase cleaves APP within the
Aβ sequence precluding Aβ formation. APP can also be processed through
the less common amyloidogenic pathway, which generates Aβ through
the sequential cleavage by BACE and γ-secretase (Fig. 3) [36,76,83].
Presently, the exact subcellular localization ofAPPprocessing remains un-
clear. Lammich et al. [84] suggested that the non-amyloidogenic process-
ing of APP occurs predominantly in the plasma membrane. It is believed
that the majority of APP is processed after maturation and transport to
the cell surface via the secretory pathway but it can also occur upon inter-
nalization of plasmamembrane-located APP through the endocytic path-
way [85].
It has been reported that the transport of APP from ER to the plasma
membrane occurs differently in non-polarized and polarized cells, such
as neurons. Soma, dendrites and axons play different functions and have
different sets of proteins and lipids that regulate protein trafﬁcking [85].
In neurons, the delivery of proteins to the proper destination is ensured
by microtubules, motor proteins (dinein and kinesin) and sorting
signals. During its trafﬁcking from the ER to the plasma membrane,
APP undergoes several post-translational modiﬁcations. After protein
synthesis in membrane-bound polysomes, APP is N-glycosylated inFig. 3. Amyloid precursor protein (APP) processing and trafﬁcking in the secretory pathway. Aft
andGolgi and is transported to theplasmamembranewhere it can be cleavage byα-secretase. T
can also be cleavage through the sequential cleavage ofβ- andγ-secretases to release Aβ. Non-p
endocytic pathway to the trans-Golgi network (TGN) and to the ER in a retromer-dependent mthe ER and then transported to the Golgi apparatus where it is O- and
N-glycosylated, phosphorylated and sulphonated at tyrosine motifs
[86]. In vitro studies have shown that only 10%of APP goes to theplasma
membrane and that the majority of APP protein remains in the Golgi
and trans-Golgi network (TGN). APP is transported along the axon in
post TGN vesicles or in elongated tubular structures using kinesin 1 as
a motor protein. According to Kaether et al. APP tubules move unidirec-
tionally using fast axonal transport that can reach velocities of 10 μm/s
[87,88]. The fate of APP-loaded vesicles transported along axons
remains unknown. It was suggested that a small fraction of axonal
APP undergoes transcytosis for transport to dendrites but no signaling
sorting transport has been identiﬁed yet [85,89]. Studies performed in
non-polarized cells suggest that APP inserted in the plasma membrane
can be preferentially cleaved via the non-amyloidogenic pathway and,
due to the presence of a “YENPTY” internalization motif near the
C-terminus, APP could be internalized via endocytosis reaching the
endosome [90]. After endocytosis, APP fragments can return to the cell
surface, can be degraded in the lysosome or can be transported in a
retromer-dependent manner to the TGN. Recent studies suggest that
the APP retromer transported from the early endosome to TGN is
relevant for the amyloidogenic processing of APP. Using HEK293 cells
expressing APP695, Choy et al. [91] showed that depletion of the late
endosomal sorting complexes required for transport of ESCRT compo-
nents, which re-route APP from the endocytic pathway to the TGN, as
well as the depletion of the adaptor protein AP-4 that impedes directer synthesis, APP is folded and undergoes several posttranslational modiﬁcations in the ER
his cleavage occurswithin theAβ peptide sequence,which avoids the formation of Aβ. APP
rocessedAPP located at the plasmamembrane is rapidly internalized and trafﬁcked via the
anner. Once in the ER, APP can generate Aβ due to the action of ER secretases.
1449A.I. Plácido et al. / Biochimica et Biophysica Acta 1842 (2014) 1444–1453TGN-to-endosome trafﬁcking of APP, leads to the amyloidogenic
processing of APP in TGN, enhancing Aβ1-40 formation. These results
are in contradiction with the study performed by Small and Gandy [92]
showing that the depletion of VPS35, which stimulates the retromer-
mediated recycling of APP to the TGN, increases the amyloidogenic
processing of APP in TGN. More studies are thus required to elucidate
the mechanisms implicated in the trafﬁcking of APP in neurons.
In the last few years several studies demonstrated that α- and
β-secretases are present in the ER allowing APP processing [93,94].
Recently, it was shown that PS1, PS2, and γ-secretase activity, are
located predominantly in a specialized subcompartment of the ER that
is physically and biochemically connected to mitochondria, called
MAM, which is an intracellular lipid raft-like structure intimately
involved in cholesterol and phospholipid metabolism, in Ca2+
homeostasis, and in mitochondrial function and dynamics, and that is
increased signiﬁcantly in AD [95]. Taking into account numerous
evidence showing that the amyloidogenic APP processing occurs
predominately in lipid-raft domains [96], it can be hypothesized that
the ER-mitochondria interface is a subcellular site of enhanced Aβ gener-
ation. Shin et al. [94] reported that in COS7 cells transfectedwith APP695,
α- and β-secretases compete with each other for the intracellular APP
cleavage and that this competition modulates the production of Aβ in
the ER. In vitro studies further showed that APP695 accumulates in this
organelle upon ER stress while APP751 accumulation occurs preferential-
ly in theGolgi [34] suggesting that sorting and processing of neuronal and
non-neuronal APP is mediated by different mechanisms under stressFig. 4. The ER stress-induced UPR signaling pathways as therapeutic targets. The chemical cha
GRP78/BiP. PBA is also described as an inhibitor of peIF2α, CHOP/GADD153, XBP1, caspase-1
GADD34-phosphatase complex salubrinal down-regulates CHOP/GADD153, caspase-12 and A
and xestospongin C interfere with Ca2+ signaling at the ER and regulates the activity of PERK aconditions. Moreover, in HEK293 cells transfected with APP, it was
observed that APP interacts with GRP78/BiP preventing its translocation
to distal compartments, which leads to its sorting into COPI vesicles
involved in retrograde transport and accumulation in the ER [97].
The co-precipitation of APP with GRP78/BiP shows that the majority
of APP is immature, suggesting that the retrograde transport could be
part of the UPR protein quality control system. However, Katayama
et al. [98] observed a decrease in GRP78/BiP levels in samples of gray
matter of familial AD patients suggesting that the loss or dysregulation
of UPR can initiate neuronal degeneration through Aβ generation as a
consequence of amyloidogenic APP processing upon GRP78/BiP down-
regulation. We can thus hypothesize that Aβ accumulation is not only a
cause of ER stress-induced chronic UPR but also a consequence of ER
disruption.
Despite the different isoforms of APP and experimentalmodels used,
the above-mentioned studies suggest that the retention of APP in the ER
leads to an alteration of its processing and trafﬁcking and decreases
secretion of Aβ from the ER to the cytosol. It is known that the accumula-
tion of proteins in ER triggers ER stress that, if prolonged, can lead to
apoptosis. Recently, it was described that ER stress occurring in HEK293
cells overexpressing APP695 increases the levels of APP mRNA but
decreases its protein levels, which results from the cleavage of APP at
the α-site and also from the phosphorylation at the tyrosine 687 residue
that promotes the γ-secretase-mediated cleavage and the generation of
theAICD fragment [99]. This fragment is able to increase the susceptibility
to apoptosis via ER stress [99,100]. However, another study performed inperones PBA, TUDCA and TMAO improve protein folding and down-regulate the levels of
2 and ATF6. TUDCA down-regulates peIF2α, CHOP/GADD153 and XBP1. The inhibitor of
TF6 and up-regulates the ER components eIF2α, GRP78/BiP, ATF4 and XBP1. Dantrolene
nd IRE1α.
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mediated apoptosis and mutant APPsw abolishes this resistance [101].
Similar effects were observedwhen ER stress was inducedwith brefeldin
A, an inhibitor of the transport between the ER and the Golgi. The authors
also showed that the increased resistance to apoptosis under ER stress
conditions was not related with changes in the expression of GRP78/BiP
or CHOP/GADD153 suggesting that APP acts downstream, or indepen-
dently, of ER-to-nucleus signaling [101].
4. The ER as a therapeutic target for AD
It was recently suggested that themodulation of the ER-UPR could be
a suitable therapeutic strategy to avoid neuronal degeneration in several
human diseases, including AD. Indeed, manipulating ER-associated
quality control mechanisms through the stimulation of protective
and/or adaptive responses or the inhibition of the apoptotic path-
ways associated with the UPR can be beneﬁcial to treat or prevent AD.
The use of chemical chaperones such as 4-phenylbutyric acid (PBA),
tauroursodeoxycholic acid (TUDCA) or trimethylamine oxide (TMAO)
may be advantageous since these compounds improve ER folding capac-
ity and stabilize protein conformation [102]. In an ADmouse model, PBA
was shown to enhance ER function, to prevent Aβ accumulation and to
avoid the loss of dendritic spines and memory [103]. TUDCA, a taurine-
conjugated derivative from ursodeoxycholic acid, was found to amelio-
rate microglia and astrocytic activation and to prevent Aβ production in
the cortex and hippocampus of APP/PS1 mice through the regulation of
APP processing [67]. In this mouse model, TUDCA rescued neurons and
improved memory [104]. Although less used, the chemical chaperone
TMAO has been shown to be more efﬁcient than PBA and TUDCA to
promote protein folding, to reduce accumulation of protein aggregates
and to prevent apoptosis [105] and thus can be considered a promising
therapeutic strategy for AD.
Ca2+ is an important player in neurodegeneration andmany chaper-
ones do not work properly when Ca2+ homeostasis is impaired.
Targeting ER Ca2+ may allow the restoration of ER homeostasis and
increase protein folding. The RyR antagonist dantrolene, licensed for
the treatment of spasticity, inhibits ER Ca2+ release and the activation
of PERK, eIF2α and CHOP/GADD153 [102]. In the 3xTg-AD mouse
model, dantrolene reduced memory deﬁcits and the burden of neuritic
plaques in the hippocampus, and in primary cultures of cortical neurons
this compound partially prevented neuronal death induced by Aβ [106,
107]. Furthermore, the selective inhibitor of the IP3RxestosponginC can
also be considered an effective strategy for the treatment of AD. This
inhibitor was described to reduce Ca2+ levels in SHSY5Y cells transfected
with the PS1Δ9 mutation to values similar to those observed in PS1wt
cells and in primary cultures of cortical neurons treated with Aβ [107,
108].
Compounds that interact directly with UPR mediators can also be
valuable therapeutic agents. Salubrinal (3-phenyl-N-[2,2,2-trichloro-1-
[[(8-quinolinylamino) thioxomethyl] amino]ethyl]-2-propen amide)
was reported to inhibit the IRE1α/ASK1/JNK signaling pathway and
also the GADD34-phosphatase complex that dephosphorylates eIF2α.
In PC12 cells it was shown that salubrinal is a protective agent against
ER stress.Moreover, studies performed in primary cortical or hippocam-
pal cultures and in the SK-N-SH human neuroblatoma cell line treated
with salubrinal observed an increase in phosphorylated eIF2α
(peIF2α) and an attenuation of ER stress-mediated apoptosis [102,
109–111]. A recent screening has identiﬁed a selective inducer of
GRP78/BiP [112] named BiP inducer X (BIX) (1-(3,4-dihydroxy-phe-
nyl)-2-thiocyanato-ethanone) that, through the induction of the ER
stress-mediated element, is able to up-regulate GRP78/BiP in an ATF6-
dependent manner, but IRE1- and PERK-independent manner [102].
BIX also reduces the protein levels of CHOP/GADD153 and cell death in
mouse retina [113].
Several studies showed that antioxidant compounds such as
edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), dibenzoylmethane(DBM) derivatives, and N-acetyl cysteine (NAC) have beneﬁcial effects
under ER stress conditions. Edaravone is a free radical scavenger that
provided neuroprotection in several models of disease. It was shown
in SH-SY5Y cells that edavorene prevents Aβ production through
stimulation of the non-amyloidogenic APP processing [114]. In primary
cultures of glia, edavorene attenuated ER stress induced by tunicamycin
and reduced cell death through the inhibition of CHOP/GADD153 and
XBP1 [115]. Edavorene is also described as an inhibitor of PERK, eIF2α,
ATF4 and caspase-12 [116–118]. NAC is another scavenger of oxidant
species that presents beneﬁcial effects during ER stress-mediated
apoptosis, as suggested by the study of Park et al. [119] showing that
NAC reverts the down-regulation of phospho-PERK, CHOP/GADD153,
ATF4, GADD34, GRP78/BiP, and spliced XBP1 in EBV-transformed B
cells by cross-linking of CD70.
5. Conclusions
ER has a pivotal role inmany cellular processes, such as Ca2+ buffer-
ing, protein synthesis and transport and apoptotic signaling, which are
known to be disrupted in AD. Moreover, growing evidence supports
the involvement of ER stress in AD pathogenesis. A potential problem
in understanding the pathophysiology of AD might arise from the
difﬁculties in determining the subcellular localization of speciﬁc bio-
chemical players under pathological conditions and how protein modiﬁ-
cations affect their trafﬁcking and sub-cellular localization. Concerning
APP, it seems clear that ER plays a fundamental role in its trafﬁcking
and processing. APP is folded in this organelle and undergoes several
posttranslational modiﬁcations. Therefore, we believe that chronic ER
stress, which occurs throughout disease progression, interferes with
trafﬁcking of proteins within the secretory pathway, including APP
(Fig. 3), leading to the intracellular production of Aβ that, in turn,
activates several synaptotoxic and neurotoxic pathways culminating in
apoptotic cell death. Accordingly, the modulation of the ER-UPR could
be a suitable therapeutic strategy to delay or stop neuronal degeneration
inAD. Indeed, several ER stressmodulators have emerged in the last years
(Fig. 4). However, the UPR can induce both cell survival and death,
depending of the duration and intensity of the stimuli. The transient
induction of adaptive and protective ER stress-mediated UPR may
mitigate neuronal dysfunction delaying the signs of AD and avoid chronic
ER stress, which once triggered activates UPR-associated apoptotic
pathways that potentiate disease progression. Therefore, selection of
compounds that act in the multiple branches of UPR could represent a
good strategy to prevent the abnormal processing of APP as well as the
deleterious downstream events that characterize AD pathology.
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